

# *Molecular Markers in Toxicology and Epidemiology*

## *Development, Validation, and Application of Biomarkers*

*Steven R. Myers, Ph.D.*

*Professor*

*Associate Chair for Professional Education*

*Department of Pharmacology and Toxicology*

*University of Louisville School of Medicine*

*University of Louisville*

*Louisville, Kentucky USA*

*Email: [sr.myers@louisville.edu](mailto:sr.myers@louisville.edu)*

# *Introduction*

**Virtually any change produced by an environmental contaminant, whether at a biochemical, cellular, organismal, community or population level, can be regarded as a biomarker. However, for a biomarker to be useful as a monitoring tool, it should meet one or more of the following criteria :**

***Specificity*** - is the change a direct result of exposure to the contaminant? An example of an indirect response would be if the contaminant evoked a stress response which in turn brought about changes in various biomarkers .

***Sensitivity*** - is the change the first to be produced by the contaminant?

***Practicality*** - are there cheaper ways to get the same answer ?

## ***ADVANTAGES OF BIOCHEMICAL AND CELLULAR BIOMARKERS***

- Biochemical and cellular events tend to be more sensitive, less variable, more highly conserved between species, and often easier to measure than stress indices commonly examined at the organismic level.
- Biochemical and molecular alterations are the first detectable quantifiable responses to environmental changes.
- Biochemical markers can serve as markers for both exposure and effect in organisms.

# *DISADVANTAGES OF BIOCHEMICAL AND CELLULAR BIOMARKERS*

Age, diet, environmental factors, seasonal variation, and reproductive cycle may alter a number of structural states representing normality and could be potentially confounding issues in attempts to use morphological criteria as biomarkers of effect .

- **Overlap between anticipated toxic state and some aspects of the range of normal morphology may exist .**
- **It is difficult to relate biochemical responses to the health of the organism and to adverse effects on the population, the type of information which is often the bottom line in environmental monitoring. This problem can be overcome, however, by selecting biomarkers which detect cellular and biochemical events which are intimately involved in protecting and defending the cell from environmental insults .**


# *Definitions*

- **Biomarkers:** Molecular, biochemical, or cellular alterations that are measurable in biological media, such as human tissues, cells, or fluids
- **Molecular epidemiology:** Incorporation of biomarkers into analytical epidemiological research

# *Fundamental principles of toxicology*

- **Principle I:** The toxic action of a substance is a consequence of the physical/chemical interaction of the active form of that substance with a molecular target within the living organism
- **Principle II:** The magnitude of the toxic effect will be a function of the concentration of altered molecular targets which in turn is related to the concentration of the active form of the toxicant at the site where the molecular targets are located


# THE TOXICOLOGICAL PROCESS





# Continuum between exposure and disease outcome

(adapted from Talaska et al., 2002)



# *Markers of internal dose*

- A direct measure of toxic chemicals or its metabolites in cells, tissues, or body fluids (e.g., blood, urine, feces, milk, amniotic fluid, sweat, hair, nails, saliva)
  - integrate multiple portals of entry
  - integrate fluctuating exposures
  - relate time of exposure to internal dose

# *Examples of biomarkers of internal dose*

- Exhaled breath
  - volatile organic compounds (ethanol)
- Blood levels
  - styrene, lead, cadmium, arsenic
- Fat concentration
  - PCBs and PBBs, DDT, and TCDD
- Metabolites in urine
  - Aflatoxin, benzene, arsenic
- Mutagens in urine
  - Chemotherapeutic agents, carcinogens
- Hair samples
  - arsenic
- Blood
  - carboxyhemoglobin
  - carbon monoxide
- Blood
  - methemoglobinemia
  - organic nitrates

*Markers of Biologically effective dose: Assessment of the interactions of toxicants with their molecular targets*

- DNA adducts

- cellular DNA

- Benzo(a)pyrene DNA adducts in peripheral lymphocytes of coke oven workers
- cisplatin DNA adducts in WBCs of chemotherapy patients
- O6 methyldeoxyguanosine in GI mucosa from nitrosamine ingestion

- Protein adducts

- Albumin adducts

- PAHs, aflatoxins

- Hemoglobin adducts

- ethylene oxide, aromatic amines, PAHs, nitrosamines

# *Markers of early biological effect: assessment of molecular sequelae of toxicant cell interactions*

- Genetic alterations in target and reporter genes
  - mutated oncogenes
  - hprt
  - thymidine kinase
  - glycophorin A
  - loss of tumor suppressor genes
  - gene rearrangements
- Nuclear aberrations
  - single strand breaks
  - unscheduled DNA synthesis
  - DNA hyperploidy
  - micronuclei
  - sister chromatid exchanges
  - chromosomal gaps and breaks
- Altered Enzymatic activities
  - elevated protoporphyrin (lead)
  - decreased acetylcholinesterase (organophosphates)
  - elevated xenobiotic metabolizing enzymes (TCDD, PAHs)

*Markers of altered structure and function: assessment of morphological and/or functional changes following toxicant cell interactions*

- Serum markers of disease
  - elevated serum GSTs, ALA, SDH (liver toxicity)
  - creatinine kinase (myocardial toxicity)
- Proliferation markers
  - mitotic frequency
  - thymidine labeling index
  - nuclear antigens
  - ornithine decarboxylase
  - polyamine levels

- Differentiation markers
  - cytokeratins
  - involucrin
  - transglutamase
- Differentially expressed genes
  - EGF, TGF-B, serum a-fetoprotein
- Cellular/tissue changes
  - metaplastic lesions
  - changes in sperm counts and mobility
  - macrophage activity
  - red cell counts

# *Criteria for selecting intermediate biomarkers*


- Is there a causal relationship between the biomarkers and disease ?
- Does the biomarker appear at a defined stage of the disease process?
- Can the biomarker be modulated by eliminating exposure ?
- Can the biomarker be obtained by non-invasive techniques?
- Do the biomarker and its assay provide acceptable sensitivity, specificity, and accuracy?
- Is the biomarker stable and easy to measure?

## *The validation process: confirming the biomarker disease link*

- What is the intra- and interindividual variability?
- What is the background?
- What are the optimal sampling conditions ? (e.g. timing, seasonality, repetitive or serial sampling)
- Is there agreement of mutually confirmatory methods for measuring the same biomarker?
- Is there a relationship between the biomarker and disease?
- Can the biomarker levels be modulated during intervention?
- Is there a dose response?



# MOLECULAR BIOMARKERS OF GENOTOXIC EXPOSURE



# *Markers of Biologically effective dose DNA and protein adducts*


- Tobacco smoking
- dietary exposure
- medicinal exposure
- Occupational exposure
- Oxidative damage

- The choice of biomarker is dependent upon the unique conditions under which it is to be applied. Some important factors to consider in order to use a biochemical biomarker effectively include the following :
  - the environmental question being addressed
  - the nature of the chemicals of interest
  - the species appropriate to the situation
  - the types of metabolites anticipated
  - the nature of the biological sample
  - possible modifying factors specific to the situation
  - limits of detection for the analytical procedures
  - quality assurance/quality control considerations
  - cost

# **Application of Biomarkers in Epidemiology**

# WHY USE BIOMARKERS?

- † **Clinical uses**
- † **Research uses**
- † **Public health uses**
- † **Policy uses**



<b>Chemical</b>	<b>Biomarker</b>	<b>Some interpretive options</b>
<b>Polybrominated diphenyls (PBDE)</b>	PBDE in blood and breast milk	Identify exposed population, key information gaps, need for new toxicity and exposure data
<b>Lead</b>	Blood lead	Follow population exposures over time
<b>Organo-phosphates</b>	Parent compound, primary & secondary metabolites, blood and urine	Develop reference ranges, evaluate exposed subpopulations, evaluate public health interventions
<b>Phthalates</b>	Primary & secondary urinary metabolites	Develop reference ranges, identify and follow exposed subpopulations
<b>Dioxin</b>	Dioxin in blood or lipid	Use of pharmacokinetic modeling to estimate body burden

<b>Chemical</b>	<b>Biomarker</b>	<b>Relative utility in clinical medicine</b>
<b>Lead</b>	Blood Lead	Identify and manage lead poisoning in individual patients – very useful clinically
<b>Arsenic</b>	Urinary Arsenic	Identify recent arsenic exposure – somewhat useful clinically
<b>Organo-phosphates</b>	Serum or red blood cell cholinesterase level	High intra- and inter-individual variability, overlap with toxic levels, results not available in a timely fashion, lab errors common, not useful clinically
<b>Nitrate/nitrite</b>	Methemoglobin	Nonspecific and expressed as % of total hemoglobin, must be interpreted within the context of full exposure history and physical exam – somewhat useful clinically
<b>Benzene</b>	Benzene in blood or expelled breath	Short half-life so only useful within a few hours of high exposure – not useful clinically outside of occupational setting

## Examples of order of magnitudes for levels of detection for some biomarkers


Marker	Matrix	Units
Polycyclic aromatic hydrocarbon	Urine	ng/L
Cotinine	Serum	ng/mL
Benzene	Blood	ng/mL
Organophosphate metabolites	Urine	µg/L
Arsenic	Urine	µg/L
Bisphenol A	Urine	µg/L
Lead	Blood	µg/dL
Polybrominated diphenyl ethers	Serum	ng/g lipid
Dioxin	Serum	pg/g lipid



**Biomarkers are most useful when both “up stream” and “down stream” knowledge is complete**

- † Primary sources of environmental contaminant understood
- † Pathways/routes of exposure understood
- † Human exposure is related to animal toxicology studies
- † Exposure-dose relationship understood
- † Timing and duration of exposure known

## The Environmental Public Health Continuum (EPHC)



# **Issues Facing Biomarker Development**

# METHODOLOGICAL ISSUES

- † Analytical technique
- † Environmental contaminants and controls
- † Laboratory contamination and quality assurance
- † Correct choice of biomarker for study design and question
- † Rationale for selecting environmental chemicals of interest
- † Coordination with related research – epidemiology, toxicology, pharmacokinetic modeling, exposure assessment

# RISK COMMUNICATION ISSUES

## Who gets the results and why?

- Exposures need context
  - ✦ Source and route
  - ✦ Bioavailability
  - ✦ Toxicity



## At risk communities may have unrealistic expectations

- Lag between research and intervention

## Why biomarkers are not always useful

- Incomplete knowledge of toxicity
- Inappropriate clinical use of research tools

# ETHICAL ISSUES

- ✦ Informed consent
- ✦ Ability to inform dangerously exposed/at risk individuals
- ✦ Biobanking of genetic materials
- ✦ Ethical standards differ between researchers and community
  - ✦ Individual value versus community value



✦

# MANY NATIONAL & REGIONAL BIOMONITORING PROGRAMS EXIST

- † In the U.S., decades of biomonitoring
- † Increasing number of environmental chemicals monitored
- † Increasing number of programs and agencies involved

# EXAMPLES OF BIOMONITORING PROGRAMS

## In the U.S.

- † **HEI:** Human Exposure Initiative
- † **HHANES:** Hispanic Health & Nutrition Examination Survey
- † **NHATS:** National Human Adipose Tissue Survey
- † **NHANES:** National Health & Nutrition Examination Survey
- † **NHEXAS:** National Human Exposure Assessment Survey

## In Europe & Canada:

- † **Canada:** Health Canada's biomonitoring initiatives
- † **European Union:** European Human Biomonitoring
- † **Germany:** Human Biomonitoring Commission
- † **Sweden:** Swedish Environmental Protection Agency on Environmental Pollutants


# **Specific Examples of Chemicals Causing Harm to Humans and Animals**




# Polycyclic aromatic Hydrocarbons

# *What are polycyclic aromatic hydrocarbons?*



- Polycyclic aromatic hydrocarbons (PAHs) are a group of **over 100 different chemicals** that are formed during the incomplete burning of coal, oil and gas, garbage, or other organic substances like tobacco or charbroiled meat. **PAHs are usually found as a mixture containing two or more of these compounds, such as soot .**
- Some PAHs are manufactured. These pure PAHs usually exist as colorless, white, or pale yellow-green solids. PAHs are found in coal tar, crude oil, creosote, and roofing tar, but a few are used in medicines or to make dyes, plastics, and pesticides




Hydroxynaphthalene (OHNap)




Hydroxybenz[*a*]anthracene (OHBaA)




Hydroxybenzo[*j*]fluoranthene (OHjF)




Hydroxyfluorene (OHFle)




Hydroxyfluoranthene (OHFrt)




Hydroxybenzo[*k*]fluoranthene (OHkF)




Hydroxybenzo[*a*]pyrene (OHBaP)




Hydroxyphenanthrene (OHPhen)




Hydroxybenzo[*c*]phenanthrene (OHbCPhen)




Hydroxybenzo[*e*]pyrene (OHBeP)




Hydroxybenzo[*g*]chrysene (OHgChr)



Hydroxychrysene (OHChr)



Hydroxydibenz[*a,h*]anthracene (OHDBA)



Hydroxyindeno[1,2,3-*cd*]pyrene (OHID)

**Structures of monohydroxy derivatives of polycyclic aromatic hydrocarbons (PAHs)**  
**Position numbers indicate the positions of hydroxy group for the tested monohydroxy derivatives of PAHs.**

# How are we exposed to PAHs today? ? ?

- Exposure to polycyclic aromatic hydrocarbons usually occurs by breathing air contaminated by wild fires or coal tar, or by eating foods that have been grilled .
- **PAHs have been found in at least 600 of the 1,430 National Priorities List sites identified by the Environmental Protection Agency (EPA.)**
- **Breathing air containing PAHs** in the workplace of coking, coal-tar, and asphalt production plants; smokehouses; and municipal trash incineration facilities .
- Breathing air containing PAHs from **cigarette smoke, wood smoke, vehicle exhausts, asphalt roads, or agricultural burn smoke.**
- Coming in contact with air, water, or soil near hazardous waste sites.
- **Eating grilled or charred meats;** contaminated cereals, flour, bread, vegetables, fruits, meats; and processed or pickled foods.
- **Drinking contaminated water** or cow's milk .
- Nursing infants of mothers living near hazardous waste sites may be exposed to PAHs through their mother's milk.

## Is Exposure to PAHs Associated with an Increase in Cancer Risk?


- Epidemiologic studies have reported an **increase in lung cancer** in humans exposed to coke oven emission, roofing tar emissions, and cigarette smoke. Each of these mixtures contains a number of PAHs .
- Animal studies have reported **respiratory tract tumors** from inhalation exposure to benzo(a)pyrene and **forestomach tumors, leukemia, and lung tumors** from oral exposure to benzo(a)pyrene .
- EPA has classified benzo(a)pyrene as a Group B2, probable human carcinogen .

# PAH Exposure



## .1 Typical biomonitoring method

Hydroxylated metabolites of PAHs in urine



## .2 Technical issue

Analysis of just one metabolite sometimes seems to be an indicator of the absorption of only the parent PAH .

## .3 Our strategy

The simultaneous determination of several PAH metabolites in urine will provide more comprehensive information to estimate the exposure of an individual to PAHs.

Urine (10 mL)


Adjusted to pH 5.0 with 1.0 M HCl  
+ 0.1 M Acetate buffer, pH 5.0  
Hydrolyzed with **β-glucuronidase/aryl sulfatase**  
Incubated at 37 °C for 4 h

Hydrolyzed urine

Extracted with **Sep-Pak C<sub>18</sub>** cartridge (primed with methanol and water)  
Washed with water and methanol/water (1/4, v/v)  
Dried with air for 10 min

The SPE cartridge

Connected to a **Sep-Pak Silica** cartridge  
Washed with hexane  
Eluted with hexane/ethyl acetate (9/1, v/v) (20 mL)



Eluate

Residue


+Methanol (200 uL)

HPLC injection (20 uL)

**Treatment of human urine using solid phase extraction for the determination of OHPAHs**




# HPLC analysis of urinary hydroxy PAHs




1. -1OH-naphthalene
2. -2OH-naphthalene
3. -3OH-fluorene
4. -2OH-fluorene
5. -9OH-fluorene
6. -9OH-phenanthrene
7. -3OH-phenanthrene
8. -2OH-phenanthrene
9. -1OH-phenanthrene
10. -4OH-phenanthrene
11. -1OH-benzo(c)phenanthrene
12. -3OH-fluoranthene
13. -1OH-pyrene
14. -2OH-benzo(c)phenanthrene
15. -1OH-benz(a)anthracene
16. -4OH-chrysene
17. -6OH-chrysene
18. -3OH-benzo(c)phenanthrene
19. -3OH-chrysene
20. -1OH-chrysene
21. -3OH-benz(a)anthracene
22. -9OH-benz(a)anthracene
22. -2OH-chrysene


# HPLC analysis of urinary hydroxy PAHs



1. -8OH-benzo(b)fluoranthene
2. -7OH-benzo(b)fluoranthene
3. -1OH-benzo(b)fluoranthene
4. -9OH-benzo(b)fluoranthene
5. -2OH-benzo(b)fluoranthene
6. -12OH-benzo(b)fluoranthene
7. -8OH-benzo(b)fluoranthene
8. -9OH-benzo(e)pyrene
9. -3OH-benzo(b)fluoranthene
10. -12OH-benzo(a)pyrene
11. -5OH-benzo(a)pyrene
12. -11OH-benzo(b)fluoranthene
13. -6OH-benzo(b)fluoranthene
14. -3OH-benzo(k)fluoranthene
15. -4OH-benzo(e)pyrene
16. -10OH-benzo(b)fluoranthene
17. -9OH-benzo(k)fluoranthene
18. -7OH-benzo(a)pyrene
19. -10OH-benzo(e)pyrene
20. -3OH-benzo(e)pyrene
21. -3OH-benzo(a)pyrene
22. -2OH-benzo(e)pyrene
23. -1OH-indeno-[1,2,3-c,d]-pyrene
24. -2OH-indeno-[1,2,3-c,d]-pyrene
25. -6OH-indeno-[1,2,3-c,d]-pyrene
26. -8OH-indeno-[1,2,3-c,d]-pyrene
27. -3OH-dibenzo[a,h]anthracene



# Aflatoxin B1




# Aflatoxin B1: Background

- Hepatotoxic mycotoxin (toxin from a fungus) produced by the fungi *Aspergillus flavus* and *Aspergillus parasiticus*
- Causes aflatoxicosis and liver disease

*Aspergillus spp.* grow ubiquitously on plants and crops from tropical and subtropical areas: peanuts, figs, spices, corn, maize, Brazil nuts, pecans, walnuts, soybeans, pistachios, wheat and grains

# Background

- The carcinogenic metabolite of Aflatoxin B1 is found in the milk of mammals who consume contaminated crops
- *Aspergillus* growth and Aflatoxin B1 production is dependant upon the temperature, humidity, host plant type, and the strain of fungus; high humidity usually required for growth



# AFB1-8,9-epoxide Is Cancer-causing!!

- One of the most serious effects of the AFB1-8,9-epoxide metabolite is it reacts with DNA and proteins to form an adduct .




Figura 6. Formación aducto aflatoxina-DNA y compuesto utilizado como biomarcador de exposición en orina.  
Fuente: Referencia 14.



# Other Adverse Effects of AFB1- 8,9-epoxide

- Lipid accumulation in the liver due to decreased lipid transport and reduced oxidation
- Symptoms of liver failure occur with acute aflatoxicosis:
  - Jaundice
  - ascites (fluid build up (
  - portal hypertension
  - necrosis of the liver



# Other Chronic Effects of Aflatoxin

- Immunological Suppression

- Using animal models, AFB1 has been shown to impair normal immune function either by reducing phagocytic activity or reduce T cell number and function .

- Nutritional Interference

- Aflatoxin is shown to have a dose response relationship between exposure to aflatoxin and rate of growth among small children. In addition, it also interferes in nutrient modification such as Vitamin A or D in animal models .

# Aflatoxins and Food Production

Major crops affected by aflatoxins include maize (corn) and groundnuts (peanuts). Agricultural practices can be modified to reduce aflatoxin production / contamination.

## Farming practices

- irrigation
- pesticide use
- time of harvest

## Storage practices

- drying techniques
- processing, such as shelling peanuts



*Aspergillus* on maize




Drying maize

# Aflatoxins in Farmed Animals

- **Poultry**
  - Highly sensitive
  - Aflatoxin toxicity impairs uptake of essential nutrients as well as causing tissue damage
- **Ruminants**
  - Ruminants are relatively insensitive; however, aflatoxin exposure can cause growth impairment in young or lactating animals.
  - Metabolites in milk and related dairy products
    - Aflatoxin consumed by cows is excreted in milk as the M1 metabolite.
    - The M1 metabolite can be absorbed by calves or humans causing growth failure.
    - The M1 metabolite also remains present in milk-based products such as cheese and yogurt.
- **Fish**
  - When farmed fish are accidentally fed contaminated grains, large die-offs may occur.
    - Rainbow trout are highly sensitive

**Animal deaths and reduced productivity from aflatoxin exposure can have significant negative 'economic' impact in addition to the negative health outcomes for those who consume contaminated animal products.**

# Aflatoxins: Human, Animal, and Environmental Interactions




# Allowable Aflatoxin Levels in Human Foods


Amount	Food type
20ppb	Foods in general
0.5ppb (aflatoxin M <sub>1</sub> )	Milk
20ppb	Peanuts and peanut products
20ppb	Pistachio nuts
20ppb	Brazil nuts

# Allowable Aflatoxin Levels in Animal Feeds

Amount	Feed Type
20ppb	For corn and other grains intended for immature animals (including immature poultry) and for dairy animals, or when its destination is not known
20ppb	For animal feeds, other than corn or cottonseed meal;
100ppb	For corn and other grains intended for breeding beef cattle, breeding swine, or mature poultry
200ppb	For corn and other grains intended for finishing swine of 100 pounds or greater
300ppb	For corn and other grains intended for finishing (i.e., feedlot) beef cattle and for cottonseed meal intended for beef cattle, swine or poultry








# The Benefits of an Interdisciplinary Health Approach

- Educating stakeholders on the interconnectedness of humans, animals and the environment is the first step in preventing aflatoxin-related health issues



# **Effective Ways to Implement Biomarkers**

- **1. Develop Biomarkers of Environmental Contaminations (crops, feed, livestock)**
- **2. Develop Biomarkers of Human Exposure (urine, blood, saliva, breast milk)**

Aromatic Amine Hemoglobin Adducts in Women Smokers and Nonsmokers During Pregnancy :  
Correlations with Gestational Age, Neonatal Birth Weight ,  
Ethnicity, and Pharmacogenetics



**WARNING:  
CIGARETTES HURT  
BABIES**

Tobacco use during pregnancy reduces the growth of babies during pregnancy. These smaller babies may not catch up in growth after birth, and the risks of infant illness, disability, and death are increased.

Health Canada

**Cigarettes**



ELEVATORS →

703 705-715

America's Favorite Cigarette Break.

BABIES SHOWN  
BETWEEN  
2:30 PM - 3:30 PM  
&  
7:00 PM - 8:00 PM

**Benson & Hedges 100's**

Regular 20 mg "tar," 1.1 mg nicotine; Menthol 21 mg "tar," 1.1 mg nicotine

**Chemical Constituents of Tobacco Smoke That Have Been Classified or Identified as Carcinogenic, Reproductive Toxic, or Other Health Hazard**

COMPOUND	IARC Classification <sup>a</sup>	U.S. EPA Classification <sup>b</sup>	CAL/EPA Prop 65 <sup>c</sup> //TAC <sup>d</sup>
<i>Organic Compounds</i>			
Acetaldehyde	2B	B2	yes//yes
Acetamide	2B		yes//yes
Acrolein	3	C	---//yes
Acrylonitrile	2A	B1	yes//yes
4-Aminobiphenyl	1		yes//yes
Aniline	3	B2	yes//yes
o-Anisidine	2B		yes//yes
Benz[a]anthracene	2A	B2	yes//yes
Benzene	1	A	yes//yes
Benzo[b]fluoranthene	2B	B2	yes//yes
Benzo[j]fluoranthene	2B		yes//yes
Benzo[k]fluoranthene	2B	B2	yes//yes
Benzo[a]pyrene	2A	B2	yes//yes
1,3-Butadiene		B2	yes//yes
Captan	3		yes//yes
Carbon disulfide <sup>e</sup>			yes//yes
Carbon monoxide <sup>e</sup>			yes//---
Chrysene	3	B2	yes//yes
DDT	2B		yes//---
Dibenz[a,h]acridine	2B		yes//yes
Dibenz[a,i]acridine	2B		yes//yes
Dibenz[a,h]anthracene	2A	B2	yes//yes
7H-Dibenzo[c,g]carbazole	2B		yes//yes
Dibenzo[a,e]pyrene	2B		yes//yes
Dibenzo[a,h]pyrene	2B		yes//yes
Dibenzo[a,i]pyrene	2B		yes//yes
Dibenzo[a,l]pyrene	2B		yes//yes
1,1-Dimethylhydrazine	2B		yes//yes
1-Naphthylamine	3		yes//---
2-Naphthylamine	1		yes//---
Nicotine <sup>e</sup>			yes//---
2-Nitropropane	2B		yes//yes
N-Nitrosodi-n-butylamine	2B	B2	yes//---
N-Nitrosodiethanolamine	2B	B2	yes//---
N-Nitrosodiethylamine	2A	B2	yes//---
N-Nitroso-n-methylethylamine	2B	B2	yes//---
N'-Nitrosornicotine	2B		yes//---
N-Nitrosopiperidine	2B		yes//---
N-Nitrosopyrrolidine	2B		---//yes
Styrene	2B		---//yes
Toluene <sup>e</sup>			yes//yes
2-Toluidine	2B		yes//yes
Urethane	2B		yes//---
Vinyl chloride	1		yes//yes

Relationship between Gestational Age, Neonatal Birth Weight, and Hemoglobin Adducts  
to Benzo[*a*]pyrene in Maternal Smokers and Nonsmokers

Compounds	Processed tobacco (per gram)	Mainstream (per cigarette)	Evidence for IARC evaluation of carcinogenicity	
			In lab animals	In humans
<b>PAH</b>				
Benz(a)anthracene		20-70 ng	Sufficient	NA
Benzo(b)fluoranthene		4-22 ng	Sufficient	NA
Benzo(j)fluoranthene		6-21 ng	Sufficient	NA
Benzo(k)fluoranthene		6-12 ng	Sufficient	NA
Benzo(a)pyrene	0.1-90 ng	20-40 ng	Sufficient	Probable
Chrysene		40-60 ng	Sufficient	NA
Dibenz(a,h)anthracene		4 ng	Sufficient	NA
Dibenzo(a,l)pyrene		1.7-3.2 ng	Sufficient	NA
Dibenzo(a,l)pyrene		Present	Sufficient	NA
Indeno(1,2,3-c,d)pyrene		4-20 ng	Sufficient	NA
5-Methylchrysene		0.6 ng	Sufficient	NA


<i>Developmental Stages</i>	Fertilization & Implantation of Embryo	Embryonic Development						Fetal Development					
<i>Developmental Period (Weeks)</i>	1-2	3	4	5	6	7	8	9-15	16-19	20-36	38		
<i>Specific Teratogenic Effects</i>	Usually No Effects From Teratogens	[shaded]		central nervous system									
		[shaded]			heart								
		[shaded]				arms							
		[shaded]			eyes								
		[shaded]				legs							
		[shaded]					teeth						
		[shaded]						palate					
		[shaded]							external genitalia				
		[shaded]								ear			
		<i>General Teratogenic Effects</i>	Prenatal Death	Major Congenital Anomalies						Functional Defects & Minor Congenital Anomalies			

# **Assessing Tobacco Exposure During Pregnancy**


Amniotic Fluid PAH





# *Biomarkers of PAH exposure during pregnancy (1<sup>st</sup> trimester exposure assessment)*





# Amniotic Fluid Cotinine





## *Dibenzo(a,e)pyrenes*





## *Dibenzo(a,l)pyrenes*




## *Dibenzo(a,i)pyrenes*




## *Anthanthrene*



## Amniotic Fluid (benzo(a)pyrenes)




## 1-Hydroxypyrene




Levels of 1-hydroxypyrene detected in amniotic fluid samples from nonsmokers and smokers

## 6-hydroxybenzo(a)pyrene



Levels of 6-hydroxybenzo(a)pyrene detected in amniotic fluid samples from nonsmokers and smokers

## 6-Hydroxychrysene




Levels of 6-hydroxychrysene detected in amniotic fluid samples from nonsmokers and smokers



**Application of Hemoglobin Adducts  
in Maternal and Fetal Blood as  
Biomarkers to Tobacco Carcinogens**

# A Molecule To Breathe With


## HEMOGLOBIN



- **Matched Maternal and Cord Blood Samples obtained from Norton's Hospital Downtown and Norton's Suburban Hospital**
- **Ethnicities**
  - Caucasian
  - African American
  - Hispanic
- **Sample Characteristics**
  - Women (18 - 35 years of age)
  - Single pregnancy (no multiples)
  - No pre-existing health problems
  - Women that have significant health related effects during pregnancy are eliminated from study
  - Smokers (> 1 pack per day smokers)
  - 32 >week gestational age infants not included


Plot of Fitted Model

$$\text{BP fetal} = -10.9301 + 0.54665 \cdot \text{BP maternal}$$




Plot of Fitted Model

$$\text{BP maternal} = 1003.83 - 23.9878 \cdot \text{GA}$$




Plot of Fitted Model  
 $BW = -3035.22 + 169.055 \cdot GA$




### Plot of Fitted Model

$$\text{BP fetal} = 531.797 - 12.9432 \cdot \text{GA}$$



Plot of Fitted Model

$$\text{BP fetal} = 298.765 - 0.0763429 \cdot \text{BW}$$






## **Aromatic Amines and related carcinogens in Tobacco**


- aniline
- -2toluidine
- -3toluidine
- -4toluidine
- -2ethylaniline
- -3ethylaniline
- -4ethylaniline
- -2,3dimethylaniline
- -2,4dimethylaniline
- -2,5dimethylaniline
- -2,6dimethylaniline
- -1naphthylamine
- -2naphthylamine
- -2methyl-1-naphthylamine
- -2aminobiphenyl
- -3aminobiphenyl
- -4aminobiphenyl
- -1nitropyrene
- -4nitropyrene
- -1,3dinitropyrene
- -1,6dinitropyrene
- -1,8dinitropyrene
- -6nitrochrysene
- -2nitrofluorene
- -5nitroacenaphthylene
- -3,7dinitrofluoranthene
- -3,9dinitrofluoranthene

## -4Aminobiphenyl Concentration in Tobacco


Mainstream cigarette smoke contains 4-aminobiphenyl at levels of 2.4 to 4.6 ng per cigarette (unfiltered) and 0.2 to 23 ng per cigarette (filtered), and sidestream smoke contains up to 140 ng per cigarette



Aromatic Amine Hemoglobin Adducts in Women Smokers  
and Nonsmokers During Pregnancy :  
Correlations with Gestational Age, Neonatal Birth Weight ,  
Ethnicity, and Pharmacogenetics




Ethnic Maternal vs Fetal 4-ABP Hb Adducts




Correlation of Fetal 4-Aminobiphenyl with Birthweight (Total Population)


$$\text{Birth Weight} = 3607.42 - 3.73662 * \text{FetalABP}$$



# Correlation of Gestational Age (wks) vs Fetal 4-Aminobiphenyl Hb Adducts



# Use of biomarkers in risk assessment



# Conclusions